Fluidigm

Standard BioTools Inc. engages in the provision of biotechnology tools and services for clinical research. It sells preparatory and analytical instruments for mass cytometry, polymerase chain reaction, library prep, single cell genomics, and consumables including integrated fluidic circuits (IFCs), assays, and reagents. The company was founded by Stephen D. Quake and Gajus Vincent Worthington on May 19, 1999 and is headquartered in South San Francisco, CA.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Standard BioTools Inc

New Trading Symbol (NASDAQ:LAB) Expected to be Effective April 6, 2022

Fluidigm Completes $250 Million Strategic Capital Infusion and Changes Name to Standard BioTools Inc.

SOUTH SAN FRANCISCO, Calif., April 01, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today announced that its stockholders have voted to approve all of the proposals related to the previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”).

Fluidigm Stockholders Approve $250 Million Strategic Capital Infusion

Caligan Partners to Vote “FOR” Casdin and Viking Transaction and All Other Fluidigm Proposals at the Special Meeting to be Reconvened on April 1, 2022

Fluidigm Announces Support Agreement with Caligan Partners Related to $250 Million Strategic Capital Infusion by Casdin Capital and Viking Global

Company Urges ALL Stockholders to Vote “FOR” the Proposals at the Special Meeting

Fluidigm Highlights the Strategic Capital Infusion by Casdin Capital and Viking Global as the Only Actionable Financing Solution

Provides Stockholders Additional Time to Consider $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors Provides Stockholders Additional Time to Consider $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors

Fluidigm Adjourns Special Meeting of Stockholders Until April 1, 2022

Cash Investment Expected to Significantly Advance Fluidigm's Mission through New Growth Initiatives and Cost Structure Optimization Cash Investment Expected to Significantly Advance Fluidigm's Mission through New Growth Initiatives and Cost Structure Optimization

Fluidigm Urges Stockholders to Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion TODAY

Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY Fluidigm Board of Directors Unanimously Recommends Stockholders Vote “FOR” ALL Proposals TODAY

Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Fluidigm Stockholders Vote “FOR” ALL Proposals Related to $250 Million Strategic Capital Infusion

SOUTH SAN FRANCISCO, Calif., Feb. 17, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq: FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced financial results for the fourth quarter and full year ended December 31, 2021.

Fluidigm Announces Fourth Quarter and Full Year 2021 Financial Results

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2022 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM) today filed with the U.S. Securities and Exchange Commission (the “SEC”) a preliminary proxy statement for a special meeting of stockholders (the “Special Meeting”) at which Fluidigm stockholders will have the opportunity to consider and vote upon various items related to the proposed and previously announced strategic capital infusion from leading life sciences investors Casdin Capital, LLC (“Casdin”) and Viking Global Investors LP (“Viking”). In connection with filing the preliminary proxy statement, Fluidigm also filed a strategic capital overview presentation. Both the preliminary proxy statement and strategic capital overview presentation can be found at www.sec.gov.

Fluidigm Files Preliminary Proxy Statement in Connection with Proposed Strategic Capital Infusion from Casdin Capital and Viking Global Investors

According to preliminary results, the company's revenue amounted to $38.2 million in the 4th quarter, up 36.4% from the previous quarter. Sales of CyTOF XT introduced to the scientific community in the first half of 2021 showed a 133% increase in sales in Q3 2021 compared to Q2 2021.

Fluidigm Corporation: Investment Opportunity

Fluidigm Corporation (NASDAQ: FLDM) has approved a $250 million investment by Casdin Capital LLC and Viking Global Investors LP with zero-coupon convertible preferred shares with a conversion price of $3.40/share. The investment will significantly advance the Company's mission through new organic and inorganic growth initiatives while optimizing its cost structure.

Casdin Capital, Viking Global Investors Inject $250M In Fluidigm

Mission to Reinvigorate Growth through Optimization of Mass Cytometry and Microfluidics Platforms and Portfolio Expansion via Strategic Acquisitions

Fluidigm Announces $250 Million Strategic Capital Infusion from Casdin Capital and Viking Global Investors and Rebranding to Standard BioTools Inc.

Fluidigm Corp (NASDAQ: FLDM) expects Q4 FY21 sales of $38.0 million - $38.3 million, exceeding the company's prior guidance of $31 million – $34 million and the analyst estimate of $32.7 million. Base product and service revenue, excluding COVID-19 testing, is expected to be $35.1 million - $35.4 million, +13%–14% Y/Y.

Fluidigm Shares Gain As Preliminary Q4, FY21 Sales Exceed Expectations

No Published Viral Mutations to Date, Including Omicron Variant, Meaningfully Impact the Regions of the Viral Genome Targeted by the Assay No Published Viral Mutations to Date, Including Omicron Variant, Meaningfully Impact the Regions of the Viral Genome Targeted by the Assay

Fluidigm Confirms Advanta Dx SARS-CoV-2 RT-PCR Assay on the Company's Biomark Platform Detects Omicron Variant of COVID-19

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm's business strategy and financial performance at the following investor event:

Fluidigm to Participate in the Piper Sandler 33rd Annual Virtual Healthcare Conference

Dunxin Financial Hlds

GlycoMimetics

Greenpro Capital Corp

Are these on your list of penny stocks to watch today? The post Hot Penny Stocks To Buy Now?

Hot Penny Stocks To Buy Now? 4 To Add To Your List Today

Streamlines Operations to Reduce Hands-On Time, Accelerate Results

Biomark X Offers Industry-Leading Advantages in Speed, Throughput, Flexibility and Cost

Fluidigm Corp (NASDAQ: FLDM) posted Q3 revenues of $28.5 million, down 29% Y/Y, missing the consensus of $30.00 million, citing supply chain issues affecting product fulfillment. Fluidigm is undertaking a review of various options to maximize shareholder value, including strategic alternatives, cost & capital structure, and operations and supply chain.

Fluidigm Q3 Sales Trail Estimates; Cuts Annual Guidance As COVID-19 Sales Retreat

Fluidigm Corporation (FLDM) CEO Chris Linthwaite on Q3 2021 Results - Earnings Call Transcript

Board Undertaking Review of Range of Value-Enhancing Opportunities

Fluidigm Announces Third Quarter 2021 Financial Results

IMC Studies Part of New York Genome Center's Polyethnic-1000 Initiative Advancing Understanding of Racial Disparities in the Prevalence of Cancer Types IMC Studies Part of New York Genome Center's Polyethnic-1000 Initiative Advancing Understanding of Racial Disparities in the Prevalence of Cancer Types

Imaging Mass Cytometry Utilized to Seek Molecular Links between African Ancestry and Aggressive Forms of Breast and Prostate Cancer

SOUTH SAN FRANCISCO, Calif., Oct. 20, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that it will report third quarter 2021 financial results on Monday, November 8, 2021, after the close of the market.

Fluidigm Announces Conference Call and Webcast of Third Quarter 2021 Financial Results

Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for Researchers Native Reading of Hyperion Imaging System Data Files on the Visiopharm Platform to Streamline Data Analysis for Researchers

Fluidigm Announces New Co-Marketing Program under Collaboration Agreement with Visiopharm, Offering AI-Based Image Analysis Software

Department of Women's and Children's Health to Work with Fluidigm on CyTOF Research Applications, Product Development Department of Women's and Children's Health to Work with Fluidigm on CyTOF Research Applications, Product Development

Fluidigm Announces Collaboration Agreement with Karolinska Institutet to Accelerate Customer Adoption of New CyTOF XT

SOUTH SAN FRANCISCO, Calif., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, today announced that Chris Linthwaite, President and CEO, and Vikram Jog, Chief Financial Officer, will participate in investor meetings and present updates regarding Fluidigm's business strategy and financial performance at the following investor event:

News for Fluidigm Stock (FLDM)